NCIC randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer. ($1300/patient)
PI: P. Hoskins Co: K. Swenerton, J. Pike, D. Miller, T. Ehlen

A phase II clinical trial of anetholtrithione (sialor) in smokers with dysplasia of the bronchial epithelium [$639,670 over 3 yrs]
PI: A.F. Gazdar, S. Lam Co: A. Coldman, C. MacAulay, D. Miller, J. LeRiche